Metabolic Surgery Is Renoprotective in Patients With Obesity, CKD
FRIDAY, Sept. 27, 2024 -- For patients with obesity, type 2 diabetes, and estimated glomerular filtration rate (eGFR) 20 to 60 mL/min/1.73 m2, metabolic surgery is associated with a lower risk for progression of kidney impairment compared with glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment, according to a study published in the September issue of the Annals of Surgery.
Ali Aminian, M.D., from the Cleveland Clinic, and colleagues examined the renoprotective effects of metabolic surgery in patients with established chronic kidney disease (CKD). Patients with obesity, type 2 diabetes, and eGFR 20 to 60 mL/min/1.73 m2 who underwent metabolic surgery were compared to nonsurgical patients who received GLP-1RA treatment. The analyses included 425 patients: 183 in the metabolic surgery group and 242 in the GLP-1RA group, with a median follow-up of 5.8 years.
The researchers found that the cumulative incidence of the primary end point of CKD progression at eight years was 21.7 and 45.1 percent in the surgical group and nonsurgical group, respectively, with an adjusted hazard ratio of 0.40. At eight years, the cumulative incidence of the secondary end point of incident kidney failure or all-cause mortality was 24.0 and 43.8 percent in the surgical and nonsurgical groups, respectively (adjusted hazard ratio, 0.56).
"Metabolic surgery should be considered as a therapeutic option for patients with CKD and obesity," the authors write.
Several authors disclosed ties to the pharmaceutical and medical technology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
GLP-1 RAs Cost-Effective Versus Usual Care for Knee OA, Obesity
WEDNESDAY, Sept. 17, 2025 -- Compared with usual care, the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) tirzepatide and semaglutide are cost-effective for people with...
Without Biannual Time Shift, Prevalence of Obesity, Stroke May Be Reduced
WEDNESDAY, Sept. 17, 2025 -- The prevalence of obesity and stroke would be reduced with permanent Standard Time (SDT) and Daylight Saving Time (DST) compared with the current...
Weight-Loss Surgery Bests Medical Weight Management for Obesity-Related Risk Mitigation
WEDNESDAY, Sept. 17, 2025 -- Bariatric surgery is associated with a significantly lower risk for developing major metabolic comorbidities compared with a medical weight management...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.